Fertility preservation outcomes may differ by cancer diagnosis

CONTEXT: Cancer survival has improved significantly and maintaining fertility is both a major concern and an important factor for the quality of life in cancer patients. AIMS: To explore differences in oocyte stimulation for fertility preservation (FP) patients based on cancer diagnosis. SETTINGS AND DEIGN: Between 2005 and 2011, 109 patients elected to pursue FP at a single institution. MATERIALS AND METHOD: In vitro fertilization (IVF) outcome variables between four cancer diagnostic groups (breast, gynecologic, lymphoma/leukemia and other) and age-matched male factor or tubal factor infertility IVF control group were compared. STATISTICAL ANALYSIS: ANOVA and Chi-square analyses were employed to compare variables between the groups that were normally distributed. Kruskal–Wallis with subsequent Mann–Whitney U-test were used for data that were not normally distributed. RESULTS: Women with gynecologic malignancies were significantly older than the women in the other three groups, but tended to have a better ovarian response. Women with hematologic malignancies were most likely to have been exposed to chemotherapy and had the longest stimulations with a similar number of oocytes retrieved. The age-matched IVF controls had higher peak estradiol levels, number of oocytes obtained, and fertilization rates when compared to cancer patients with or without a history of prior chemotherapy. CONCLUSIONS: Factors including age, type of cancer and chemotherapy exposure, can influence response to ovarian stimulation. Discussing these findings with patients presenting for FP may aid in setting realistic treatment expectations.

[1]  M. Beckmann,et al.  Oncofertility: combination of ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval , 2013, Reproductive Biology and Endocrinology.

[2]  F. Azem,et al.  Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation. , 2012, Fertility and sterility.

[3]  A. Pellicer,et al.  Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. , 2012, Fertility and sterility.

[4]  S. Missmer,et al.  Female cancer survivors are low responders and have reduced success compared with other patients undergoing assisted reproductive technologies. , 2012, Fertility and sterility.

[5]  S. Missmer,et al.  Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. , 2011, Fertility and sterility.

[6]  S. Klock,et al.  Fertility preservation for female cancer patients: early clinical experience. , 2010, Fertility and sterility.

[7]  D. Tsiftsis,et al.  Pregnancy after breast cancer. A comprehensive review , 2010, Journal of surgical oncology.

[8]  N. Michaan,et al.  Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients. , 2010, European journal of obstetrics, gynecology, and reproductive biology.

[9]  L. Westphal,et al.  Ovarian stimulation for fertility preservation in patients with cancer. , 2010, Fertility and sterility.

[10]  K. Oktay,et al.  Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Jeruss,et al.  Preservation of fertility in patients with cancer. , 2009, The New England journal of medicine.

[12]  L. Schover Patient attitudes toward fertility preservation , 2009, Pediatric blood & cancer.

[13]  A. Bleyer,et al.  Cancer in young adults 20 to 39 years of age: overview. , 2009, Seminars in oncology.

[14]  J. Grifo,et al.  Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. , 2009, Fertility and sterility.

[15]  K. Oktay,et al.  Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Oktay,et al.  Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. , 2007, Fertility and sterility.

[17]  H. Bang,et al.  Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. , 2006, The Journal of clinical endocrinology and metabolism.

[18]  T. Falcone,et al.  Fertility Preservation in Cancer Patients , 2006, Women's health.

[19]  E. Winer,et al.  Web-based survey of fertility issues in young women with breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  K. Oktay,et al.  Fertility preservation in female patients. , 2004, Human reproduction update.

[21]  H. Mouridsen,et al.  Prognostic influence of pregnancy before, around, and after diagnosis of breast cancer. , 2003, Breast.

[22]  J. Garcia,et al.  Effect of maternal age and number of in vitro fertilization procedures on pregnancy outcome. , 1989, Fertility and sterility.

[23]  M. Sammel,et al.  Impact of cancer therapies on ovarian reserve. , 2012, Fertility and sterility.

[24]  A. Raziel,et al.  Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. , 2012, Fertility and sterility.

[25]  N. Pavlidis,et al.  Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. , 2011, European journal of cancer.

[26]  M. Pavone,et al.  Comparing thaw survival, implantation and live birth rates from cryopreserved zygotes, embryos and blastocysts , 2011, Journal of human reproductive sciences.

[27]  S. S. Kim Fertility preservation in female cancer patients: current developments and future directions. , 2006, Fertility and sterility.